Reverie Labs uses new machine learning algorithms to fix drug development bottlenecks

Developing new medicines can take years of research and cost millions of dollars before they are even ready for clinical trials. Several biotech startups are using machine learning to revolutionize the process and get drugs into pharmacies more quickly. One of the newest is called Reverie Labs, which is part of Y Combinator’s latest batch. The Boston-based company wants to fix a critical bottleneck in the drug development process by speeding up the process of identifying promising molecules using recently published machine learning algorithms.